CFAP161

Across TCGA pan-cancer cohorts, CFAP161 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated CFAP161 data layer compared with 21 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher CFAP161 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated CFAP161 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LUAD and LSCC are the cancer types where CFAP161 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.805	1.000	.019	11	view →
LSCC	DFS	Tertile	All	1.000	0.383	.038	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

CFAP161–LUAD (OS)

Open the LUAD breakdown →